Vanderbilt University Medical Center is teaming up with academic, governmental and corporate partners in an unprecedented, fast-tracked global effort to develop antibody-based treatments to protect people exposed to COVID-19.
“Our goal is to prepare antibodies for human clinical trials by this summer,” said James Crowe, MD, director of the Vanderbilt Vaccine Center.
“We have ultra-rapid antibody discovery technologies and already have discovered SARS-CoV-2 antibodies,” Crowe said. “Our partners have the manufacturing and product development expertise to turn these antibodies into effective biological drugs very quickly.”